U.S. Markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    48,481.03
    +171.60 (+0.36%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Haemonetics' Vascade Vascular Closure Device Includes Same-Day Discharge Label

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Haemonetics Corp's (NYSE: HAE) Vascade MVP Venous Vascular Closure System becomes the first vascular closure device to receive FDA indication for same-day discharge following atrial fibrillation (AF) ablation.

  • The Same-Day Discharge labeling was granted following the conclusion of the first two registries in the AMBULATE Same-Day Discharge (SDD) clinical study series.

  • As of July 2021, Cardiva Medical Inc completed three of its four planned registries in the AMBULATE Same-Day Discharge Clinical Study Series in almost 850 subjects.

  • Approximately 99% of subjects treated for AF with venous closure using the Vascade MVP were sent home the same day without additional intervention post-discharge.

  • Vascular access safety in all three studies was similar to that in the AMBULATE Pivotal Study.

  • Same-Day Discharge #3, an all-comers study for patients undergoing AF ablation with venous closure using VASCADE MVP, will begin enrollment in 2022. It is planned to be a multi-center prospective registry of 300 subjects.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: HAE stock closed 0.18% higher at $70.59 on Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.